PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease.

about

The serotonergic system in Parkinson's patients with dyskinesia: evidence from imaging studies.Neuroimaging of Sleep Disturbances in Movement Disorders

P2860

Q48372783-17C8986A-C484-45DA-A74C-6DB9980D9CBE Q57493665-B3178861-A5D8-47C5-A9EB-6CBE22AFDD95

P2860

PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease.

Item

http://www.wikidata.org/entity/Q42369736

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease.

@en

PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease.

@nl

type

Item

label

PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease.

@en

PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease.

@nl

prefLabel

PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease.

@en

PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease.

@nl

P1476

PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease.

@en

P2093

Gennaro Pagano

http://www.w3.org/2001/XMLSchema#string

Marios Politis

http://www.w3.org/2001/XMLSchema#string

Tayyabah Yousaf

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum

Cholinergic imaging in dementia spectrum disorders

Current status of PET imaging in Huntington's disease

Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys

Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease

Nicotinic receptor-mediated reduction in L-DOPA-induced dyskinesias may occur via desensitization

Imaging the glutamate system in humans: relevance to drug discovery for schizophrenia.

Molecular Targets for PET Imaging of Activated Microglia: The Current Situation and Future Expectations.

Dyskinesias after neural transplantation in Parkinson's disease: what do we know and what is next?

Dyskinesia and the antiparkinsonian response always temporally coincide: a retrospective study.

P2888

s11910-017-0794-2

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S11910-017-0794-2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2017-10-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28975571

http://www.w3.org/2001/XMLSchema#string

P921

P932

5626800

http://www.w3.org/2001/XMLSchema#string

PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease.

about

P2860

P2860

PET Molecular Imaging Research of Levodopa-Induced Dyskinesias in Parkinson's Disease.

description

name

type

label

prefLabel

P1433

P1476

P2093

P275

P2860

P2888

P304

P31

P356

P433

P478

P5008

P577

P698

P921

P932

P356

P1433

P1476

P2093

P275

P2860

P2888

P304

P31

P356

P433

P478

P5008

P577

P698

P921

P932